CONCLUSIONS

- MIRV is the first biomarker-directed agent demonstrating antitumor activity in patients with FRA-high PROC

- Tumor reduction occurred in 71% of patients, and OCR (CR, PR, SD ≥ 12 weeks) was 51%

- Patients with BRCA mutations, both with and without prior PARPi, demonstrated robust antitumor activity

- In responders, depth and duration of response did not appear to be affected by dose reductions

- Preliminary mOS was 13.8 months

- Safety and tolerability of MIRV in SORAYA are consistent with that observed in previous studies

- Ocular adverse events were monitored in all patients, and the incidence of grade ≥ 3 ocular events was 1.4%, comparable to previous studies

- Two cases of grade ≥ 3 ocular events (retinal detachment) were reported during study participation

- The study described here was sponsored by ImmunoGen, Inc. The authors would like to especially thank the patients who consented to be included in this study, as well as their families.

- Editorial assistance in the preparation of this poster was provided by ImmunoGen, Inc.

- For additional information, please contact medicalinfo@immunogen.com